Tauns Laboratories, Inc. AI Stock Analysis
Want to see JP:197A full AI Analyst Report?
Tauns Laboratories, Inc. (197A) AI Stock Analysis
Tauns Laboratories, Inc.
(TSE/TYO:197A)
Moderate financial performance, pressured by negative cash flow and rising leverage, is the largest factor. Support comes from attractive valuation via low P/E and high yield plus positive technical momentum above moving averages.
Tauns Laboratories, Inc. (197A) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 52.02B
- Dividend Yield
- 5.79%
- Average Volume (3M)
- 211.91K
- Price to Earnings (P/E)
- 9.3
- Beta (1Y)
- 0.41
- Revenue Growth
- -22.86%
- EPS Growth
- -16.43%
- Country
- Japan
- Employees
- 271
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Specialties
Tauns Laboratories, Inc. Business Overview & Revenue Model
Company Description
TAUNS Laboratories, Inc. is a company dedicated to the creation and production of in-vitro diagnostic pharmaceuticals and various types of measuring equipment. Additionally, the firm facilitates the international trade (import and export) of an exten...
Tauns Laboratories, Inc. Financial Statement Overview
Summary
Resilient 38% net margins contrast with sharp revenue drop to 14.4 billion, debt more than quadrupled raising leverage above 1.0, and operating cash flow swinging to -2.8 billion.
Income Statement
64PositiveBalance Sheet
47NeutralCash Flow
29Negative| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 14.37B | 14.37B | 18.63B | 18.43B | 15.67B | 17.46B |
| Gross Profit | 8.82B | 8.22B | 12.33B | 12.50B | 8.79B | 14.29B |
| EBITDA | 5.33B | 5.33B | 9.02B | 8.65B | 5.32B | 8.55B |
| Net Income | 5.50B | 5.50B | 6.32B | 5.77B | 3.03B | 4.48B |
Balance Sheet | ||||||
| Total Assets | 44.62B | 44.62B | 36.52B | 29.26B | 18.81B | 20.88B |
| Cash, Cash Equivalents and Short-Term Investments | 3.56B | 3.56B | 9.27B | 9.42B | 1.24B | 6.35B |
| Total Debt | 21.26B | 21.26B | 14.42B | 9.54B | 6.47B | 4.90B |
| Total Liabilities | 25.20B | 25.20B | 19.10B | 15.59B | 10.32B | 13.52B |
| Stockholders Equity | 19.42B | 19.42B | 17.42B | 13.67B | 8.49B | 7.36B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -6.61B | 2.14B | 5.97B | -4.32B | 8.39B |
| Operating Cash Flow | 0 | -2.83B | 6.82B | 9.94B | -3.16B | 10.69B |
| Investing Cash Flow | 0 | -6.18B | -9.26B | -4.11B | -1.62B | -2.68B |
| Financing Cash Flow | 0 | 3.30B | 2.28B | 2.36B | -330.20M | -3.66B |
Tauns Laboratories, Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:197A, the sentiment is Negative. The current price of 484.00 is below the 20-day moving average (MA) of 495.50, below the 50-day MA of 505.84, and below the 200-day MA of 495.75, indicating a bearish trend. The MACD of -7.30 indicates Positive momentum. The RSI at 39.79 is Neutral, neither overbought nor oversold. The STOCH value of 43.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:197A.
Tauns Laboratories, Inc. Peers Comparison
Overall Rating
- JP:197A63Neutral
JP:239559Neutral
JP:455252Neutral
JP:456952Neutral
JP:454950Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| JP:197A | 63Neutral | JPY 52.02B | 9.29 | ― | 5.79% | -22.86% | -16.43% |
| JP:2395 | 59Neutral | JPY 51.62B | 8.93 | ― | 4.16% | 1.89% | 22.53% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| JP:4552 | 52Neutral | JPY 62.37B | -17.61 | ― | 4.06% | 3.05% | -67.53% |
| JP:4569 | 52Neutral | JPY 56.22B | 156.51 | ― | 4.49% | -6.48% | -95.83% |
| JP:4549 | 50Neutral | JPY 72.79B | 39.61 | ― | 2.66% | 3.92% | -52.01% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:197A | Tauns Laboratories, Inc. | 484.00 | -53.55 | -9.96% | |
| JP:2395 | Shin Nippon Biomedical Laboratories, Ltd. | 1201.00 | -318.69 | -20.97% | |
| JP:4549 | Eiken Chemical Co., Ltd. | 2182.00 | -117.10 | -5.09% | |
| JP:4552 | JCR Pharmaceuticals Co., Ltd. | 493.00 | -124.03 | -20.10% | |
| JP:4569 | KYORIN Pharmaceutical Co.,Ltd. | 1046.00 | -321.77 | -23.53% | |
| JP:368A | Kitazato Corporation | 1281.00 | -194.29 | -13.17% |
Tauns Laboratories, Inc. Corporate Events
Tauns Laboratories’ Profit Slides on Lower Sales as Cash Flow Turns Negative
Tauns Laboratories reported FY2026 net sales of ¥14.37 billion, down 22.9% year on year, with operating income halving to ¥4.20 billion and ordinary income falling 51.9%, while net income declined a milder 13% to ¥5.50 billion as profitability was su...
Tauns Laboratories Books ¥3.9 Billion Government Subsidy as Special Gain
Tauns Laboratories has booked a special gain of ¥3,949 million in the fourth quarter of the fiscal year ending June 30, 2026, after receiving final approval for a government subsidy under Japan’s “Subsidy Program for Promoting Domestic Investment to...
Tauns Laboratories Corrects Presentation of Operating Income Forecast Without Changing Outlook
Tauns Laboratories has issued a correction to its recently updated mid-term management plan, clarifying the way it presents its full-year operating income forecast for the fiscal year ending June 30, 2026. The company confirmed that the forecast rema...
Tauns Laboratories Revamps Mid-Term Plan With Strong Growth Targets
Tauns Laboratories has updated its mid-term management plan, shifting the covered period to the fiscal years ending June 2027 through June 2031 in response to changes in the business environment and the progress of its existing strategy. The new plan...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 19, 2026